1-20 of 92
Lara C. Pullen, PhD
Close
Sort by
News

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) (NCT06619561)

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
June 2025
View News titled, A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) (NCT06619561)
News

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT04901936)

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
June 2025
View News titled, A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT04901936)
News

Fixed-Duration Acalabrutinib Combinations Effective for Untreated CLL

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
May 2025
View News titled, Fixed-Duration Acalabrutinib Combinations Effective for Untreated CLL
News

An Endangered Endeavor?

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
May 2025 For hematologic malignancies, cooperative clinical trials are just as important as industry-sponsored trials, but they are struggling to thrive.
View News titled, An Endangered Endeavor?
News

Detailed Analysis of TP53 Status Predicts Transplantation Outcomes in Patients With MDS/AML

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, Detailed Analysis of TP53 Status Predicts Transplantation Outcomes in Patients With MDS/AML
News

Talquetamab Plus Teclistamab Effective for Relapsed or Refractory Multiple Myeloma

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, Talquetamab Plus Teclistamab Effective for Relapsed or Refractory Multiple Myeloma
News

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease (NCT06388564)

Free
Lara C. Pullen, PhD
Published: 2025
View News titled, A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease (NCT06388564)
News

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T, NCT04161885)

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T, NCT04161885)
News

BCMA CAR T Cells Effective, Safe for Older Adults and Frail Patients with R/R Multiple Myeloma

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, BCMA CAR T Cells Effective, Safe for Older Adults and Frail Patients with R/R Multiple Myeloma
News

Elderly Patients With BPDCN Respond Well to Venetoclax, Bortezomib, Dexamethasone Combination

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
March 2025
View News titled, Elderly Patients With BPDCN Respond Well to Venetoclax, Bortezomib, Dexamethasone Combination
News

Obecabtagene Autoleucel Effective Treatment for Adults with B-ALL

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
March 2025
View News titled, Obecabtagene Autoleucel Effective Treatment for Adults with B-ALL
News

Non-Viral, Allogeneic BCMA-Directed CAR-T Therapy Eliminates Bridging in R/R MM

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, Non-Viral, Allogeneic BCMA-Directed CAR-T Therapy Eliminates Bridging in R/R MM
News

Predicting Response to Obe-Cel in Patients With R/R B-ALL

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, Predicting Response to Obe-Cel in Patients With R/R B-ALL
News

Gerofit Exercise Intervention for Older Adults with Sickle Cell Disease (SICKLE-FIT; NCT05714098)

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
February 2025
View News titled, Gerofit Exercise Intervention for Older Adults with Sickle Cell Disease (SICKLE-FIT; NCT05714098)
News

Bevacizumab in Hereditary Hemorrhagic Telangiectasia (TRUST-HHT; NCT04404881)

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
February 2025
View News titled, Bevacizumab in Hereditary Hemorrhagic Telangiectasia (TRUST-HHT; NCT04404881)
News

Anxiety, Depression Elevated in Patients with Histiocytic Neoplasms

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
February 2025
View News titled, Anxiety, Depression Elevated in Patients with Histiocytic Neoplasms
News

New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML

Free
Lara C. Pullen, PhD
Published: 2024
Abstract
December 2024
View News titled, New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML
News

Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose

Free
Lara C. Pullen, PhD
Published: 2024
Abstract
December 2024
View News titled, Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose
News

Patients in R/R Marginal Zone Lymphoma Cohort of ELM-2 Show Superior Outcomes With Odronextamab

Free
Lara C. Pullen, PhD
Published: 2024
Abstract
January 2025
View News titled, Patients in R/R Marginal Zone Lymphoma Cohort of ELM-2 Show Superior Outcomes With Odronextamab
News

Daratumumab Shows Better Outcomes Than Active Monitoring for Smoldering Multiple Myeloma

Free
Lara C. Pullen, PhD
Published: 2024
Abstract
January 2025
View News titled, Daratumumab Shows Better Outcomes Than Active Monitoring for Smoldering Multiple Myeloma